A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Phase 2 Recruiting 30 enrolled Memorial Sloan Kettering Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses).

Timeline

Start: 2020-04-01
Primary completion: 2027-04-01
Completion: 2027-04-01

Publications

Bartlett EK, D'Angelo SP, Kelly CM, Siegelbaum RH, Fisher C, Antonescu CR, Ariyan CE. Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases. Front Oncol. 2021 Oct 15;11:725484. doi: 10.3389/fonc.2021.725484. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dactinomycin	Protein / enzyme biologic	—	Other
Subject	Melphalan	Small molecule	—	Other
Subject	Pembrolizumab	Monoclonal antibody	2 mg/kg	Intravenous
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

Summary

Timeline

Publications

Drugs

Indications